Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV

New England Journal of Medicine

Volumn 354, Issue 3, 2006, Pages 251-260

  Gallant, Joel E ^a   Dejesus, Edwin ^b   Arribas, José R ^c   Pozniak, Anton L ^d   Gazzard, Brian ^d   Campo, Rafael E ^e   Lu, Biao ^f   McColl, Damian ^f   Chuck, Steven ^f   Enejosa, Jeffrey ^f   Toole, John J ^f   Cheng, Andrew K ^f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MIAMI   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; ERYTHROPOIETIN; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION; VOMITING;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; FEMALE; HIV; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OXAZINES; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RNA, VIRAL; ZIDOVUDINE;

EID: 30944468562     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa051871     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-8.
3. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, D.C.: Department of Health and Human Services, December 23, 2005. (Accessed December 23, 2005, at http://AIDSinfo.nih.gov.)
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
5. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval. Washington, D.C.: Department of Health and Human Services, October 2002. (Accessed December 23, 2005, at http://www.fda.gov/cder/guidance.)
6. Regulatory Compliance Center. Division of AIDS (DAIDS) table of grading severity of adult adverse experiences. Bethesda, Md.: National Institute of Al lergy and Infectious Diseases, August 1992. (Accessed December 23, 2005, at http://rcc.tech-res-intl.com/tox_tables.htm.)
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
8. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.
9. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303.
10. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201.
11. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV infected adults. Clin Infect Dis 2004;39:1038-46.
12. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3.
13. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-3.
14. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:935-7.
15. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37:e174-e176.
16. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-8.
17. Cassetti I, Madruga JVR, Suleiman JMAH, Zhong L, Enejosa J, Cheng AK. Tenofovir DF in combination with lamivudine and efavirenz in antiretroviral naive patients: a 4 year follow-up. In: Program and abstracts of the 3rd IAS [International AIDS Society] Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005.
18. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
19. Bogner JR, Vielhauer V, Beckman RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27:237-44.
20. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18.
21. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
22. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002;30:440-7.
23. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavu dine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-70.
24. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004;18:1029-36.
25. Moyle G, Sabin C, Cartledge J, et al. A 48 week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virologic suppression of HAART. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22-25, 2005. abstract.
26. Miller MD, Margot NA, McColl DJ, Tran S, Coakley DF, Cheng AK. Genotypic and phenotypic characterization of virologic failure through 48 weeks among patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz. Presented at the 6th International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, November 17-21, 2002.
27. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28.